Search PubMed⌕ Search

Biomedical subjects

G W Becker

Publications and source records attributed to G W Becker.

45 records · Page 3Linked to original sources
PubMed1987

Chemical, physical, and biological characterization of a dimeric form of biosynthetic human growth hormone.

A dimer of biosynthetic human growth hormone (HGH) has been isolated and characterized. This entity, which is the predominant dimeric species in biosynthetic HGH, is chemically identical to monomeric HGH and exists in a noncovalent dimeric form which is dissociated to monomeric HGH on polyacrylamide electrophoresis gels or in aqueous solutions containing 30% acetonitrile. This substance, found in all production lots of pituitary HGH, biosynthetic HGH, and biosynthetic methionyl HGH examined, is much less biopotent than monomeric HGH and can be distinguished from monomeric HGH by a monoclonal antibody. These data demonstrate that polyacrylamide gel electrophoresis is not a valid method for measuring this dimer and that size-exclusion chromatography under aqueous conditions is required.

Amino Acids↗
PubMed1986

Expression, secretion and folding of human growth hormone in Escherichia coli. Purification and characterization.

An efficient secretion vector containing a gene coding for an E. coli signal peptide fused to human growth hormone (hGH) was cloned into E. coli. The recombinant fusion protein was expressed and correctly processed hGH was secreted into the periplasmic space at a yield of 10-15 micrograms hGH/A600. Purification of hGH from the periplasmic fraction by anion exchange and size exclusion gave hGH of greater than 90% purity. Characterization by SDS-PAGE, amino terminal analysis, trypsin mapping, and circular dichroism demonstrated that the fusion protein was correctly processed to authentic hGH and that the E. coli periplasm provided an appropriate environment for proper folding of hGH and disulfide bond formation.

Amino Acid Sequence↗
PubMed1980

Biosynthesis of phosphoinositol-containing sphingolipids from phosphatidylinositol by a membrane preparation from Saccharomyces cerevisiae.

Incubation of membranes prepared from Saccharomyces cerevisiae with [32P]phosphatidyl[3H]inositol resulted in the transfer of both labels to two products which were characterized as two species of inositolphosphoceramide, differing in the ceramide portion of the molecule. The products were characterized on the basis of stability in mild alkali, mobility on silica gel-impregnated paper, chromatography on silicic acid columns, and release of inositol phosphate upon base hydrolysis. The reaction did not require the addition of metals, nor was it inhibited by ethylenediaminetetraacetic acid. The detergents Triton X-100 and Tween 20 provided little, if any, stimulation. At relatively high concentrations of phosphatidylinositol (1 to 4 mM), the in vitro rate was about 20% of the in vivo rate. Although ceramide was a logical substrate, the reaction could not be greatly stimulated by the addition of ceramides containing mono- and dihydroxy fatty acids. In addition, incubation of yeast membranes with [32P]phosphatidylinositol gave rise to a product that was chromatographically indistinguishable from the major yeast phosphosphingolipid, mannose-(inositol-P)2 ceramide.

Cations, Divalent↗
PubMed1977

Changes in phospholipids of Saccharomyces cerevisiae associated with inositol-less death.

Two inositol-requiring strains of Saccharomyces cerevisiae were examined for changes in levels of phospholipids occurring after inositol deprivation. Lack of inositol results in loss of cell viability (inositol-less death) and in very large increases in two phospholipid precursors, phosphatidic acid and CDP-diacylglycerol; the accumulation of other glycerophospholipids continues for a considerable time at normal rates. Phosphatidylinositol accumulation does not occur in the absence of inositol; however, the further metabolism of this lipid continues, with 80 to 90% of this lipid disappearing. This disappearance is matched by increases in the phosphoinositol containing sphingolipids and extracellular glycerophosphoinositol. These changes are not observed when growth is blocked by cycloheximide or by omission of lysine from a lysine auxotroph, most lipids continuing to accumulate long after growth stops. There appears to be no close coordination in the synthesis of the major yeast phospholipids or between protein synthesis and phospholipid synthesis. However, despite very large changes in the composition of yeast phospholipids that can be achieved by altering culture conditions, it appears that the average charge per phospholipid molecule remains fairly constant.

Cell Survival↗
PubMedDate not supplied

beta-Amyloid peptide in vitro toxicity: lot-to-lot variability.

beta A4 peptide (beta AP) accumulates in amyloid plaques of Alzheimer's disease and may contribute to neuronal degeneration. Conflicting observations have been reported regarding the direct in vitro and in vivo neurotoxicity of beta AP. We have assessed in vitro beta AP toxicity in high density primary rat hippocampal cultures and found marked lot-to-lot differences in the neurotoxic properties of beta AP. One lot of beta AP from a commercial supplier resulted in significant direct neurotoxicity at 10 microM, while 2 other lots from the same supplier were essentially nontoxic. Three additional lots of beta AP from unrelated sources were also nontoxic at 10 microM. Initial biochemical characterization has not yet revealed any marked differences among the various lots of beta AP. Low levels of endotoxin (ca., 1 EU/ml) were detected in several beta AP preparations but did not correlate with neurotoxicity. Our observation that lot-to-lot variability of beta AP occurred even under identical in vitro culture conditions may account for part of the present controversy in this area.

Amyloid beta-Peptides↗